StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)

Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –

Lakefront Biotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -€257.46M. The highest annual figure on record is €3.21B in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€257.46M–
FY2024Dec 31, 2024-€320.03M–
FY2023Dec 31, 2023-€405.97M–
FY2022Dec 31, 2022-€500.54M–
FY2021Dec 31, 2021-€503.83M–
FY2020Dec 31, 2020-€427.34M-113.3%
FY2019Dec 31, 2019€3.21B–
FY2018Dec 31, 2018-€142.47M–
FY2017Dec 31, 2017-€147.03M-161.4%
FY2016Dec 31, 2016€239.40M–
FY2015Dec 31, 2015-€114.59M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?